[
  {
    "ts": null,
    "headline": "Hyperlipidemia Drugs Market Report 2025: $24.74 Industry Led by Pfizer, Merck & AbbVie, With Asia-Pacific Poised for Strong Growth Amid Trade-Driven Supply Chain Shifts - Global Forecast to 2034",
    "summary": "The hyperlipidemia drugs market is growing due to rising cardiovascular disease prevalence, increasing cholesterol management awareness, and aging populations. Opportunities lie in personalized and combination therapies, digital health integration, non-statin alternatives, and expanding markets in Asia-Pacific. Hyperlipidemia Drugs Market Hyperlipidemia Drugs Market Dublin, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The \"Hyperlipidemia Drugs Market Report 2025\" has been added to ResearchAndMarkets.com's",
    "url": "https://finnhub.io/api/news?id=0e568c1f53d7a7a4c829ba3321d703f9e8cf4fcb328c1b8bc6760bf1562bd02d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762267500,
      "headline": "Hyperlipidemia Drugs Market Report 2025: $24.74 Industry Led by Pfizer, Merck & AbbVie, With Asia-Pacific Poised for Strong Growth Amid Trade-Driven Supply Chain Shifts - Global Forecast to 2034",
      "id": 137312124,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The hyperlipidemia drugs market is growing due to rising cardiovascular disease prevalence, increasing cholesterol management awareness, and aging populations. Opportunities lie in personalized and combination therapies, digital health integration, non-statin alternatives, and expanding markets in Asia-Pacific. Hyperlipidemia Drugs Market Hyperlipidemia Drugs Market Dublin, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The \"Hyperlipidemia Drugs Market Report 2025\" has been added to ResearchAndMarkets.com's",
      "url": "https://finnhub.io/api/news?id=0e568c1f53d7a7a4c829ba3321d703f9e8cf4fcb328c1b8bc6760bf1562bd02d"
    }
  },
  {
    "ts": null,
    "headline": "Here Are Tuesday’s Top Wall Street Analyst Research Calls: Apple, AbbVie, Broadcom, CyberArk, Palantir Technologies and More",
    "summary": "Pre-Market Futures: The S&P 500 and NASDAQ futures are trading down over 1% on Tuesday, following Palantir’s 6.9% decline despite beating earnings expectations and giving strong forward guidance. Concerns over an AI bubble continue to mount. Tuesday’s sell-off follows a wild start to the week, during which the Dow Jones Industrial Average traded lower due ... Here Are Tuesday’s Top Wall Street Analyst Research Calls: Apple, AbbVie, Broadcom, CyberArk, Palantir Technologies and More",
    "url": "https://finnhub.io/api/news?id=59597ebe0178c938e383ee4aeba1c88a882b09f5aeee9d1fde3ffaa6ed1606af",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762265503,
      "headline": "Here Are Tuesday’s Top Wall Street Analyst Research Calls: Apple, AbbVie, Broadcom, CyberArk, Palantir Technologies and More",
      "id": 137311824,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Pre-Market Futures: The S&P 500 and NASDAQ futures are trading down over 1% on Tuesday, following Palantir’s 6.9% decline despite beating earnings expectations and giving strong forward guidance. Concerns over an AI bubble continue to mount. Tuesday’s sell-off follows a wild start to the week, during which the Dow Jones Industrial Average traded lower due ... Here Are Tuesday’s Top Wall Street Analyst Research Calls: Apple, AbbVie, Broadcom, CyberArk, Palantir Technologies and More",
      "url": "https://finnhub.io/api/news?id=59597ebe0178c938e383ee4aeba1c88a882b09f5aeee9d1fde3ffaa6ed1606af"
    }
  },
  {
    "ts": null,
    "headline": "Should You Buy Moderna Stock Ahead of Q3 Earnings Report?",
    "summary": "MRNA is likely to have faced earnings pressure and pipeline setbacks as waning COVID-19 vaccine demand weighs on its outlook.",
    "url": "https://finnhub.io/api/news?id=6d581b90d524e90e7b4d17bfda471c1cd6d41be5b702313cfee8142e7661c2a0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762263360,
      "headline": "Should You Buy Moderna Stock Ahead of Q3 Earnings Report?",
      "id": 137312219,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "MRNA is likely to have faced earnings pressure and pipeline setbacks as waning COVID-19 vaccine demand weighs on its outlook.",
      "url": "https://finnhub.io/api/news?id=6d581b90d524e90e7b4d17bfda471c1cd6d41be5b702313cfee8142e7661c2a0"
    }
  },
  {
    "ts": null,
    "headline": "Merck price target raised to $100 from $98 at Morgan Stanley",
    "summary": "Morgan Stanley analyst Terence Flynn raised the firm’s price target on Merck (MRK) to $100 from $98 and keeps an Equal Weight rating on the shares. Q3 results beat expectations, but driven by one-timers and Januvia as Keytruda and Winrevair came in below expectations, the analyst tells investors. Merck guided to “solid” top line growth in 2026 from new launches, but also highlighted an acceleration in operating expense, notes the analyst, who models 2026 EPS of $9.44. Published first on TheFly –",
    "url": "https://finnhub.io/api/news?id=b7ef2271fd9634952dcb5cbdd5f43c7440f141bf1b84b4f6ae6ce041668536e3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762261529,
      "headline": "Merck price target raised to $100 from $98 at Morgan Stanley",
      "id": 137312220,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Morgan Stanley analyst Terence Flynn raised the firm’s price target on Merck (MRK) to $100 from $98 and keeps an Equal Weight rating on the shares. Q3 results beat expectations, but driven by one-timers and Januvia as Keytruda and Winrevair came in below expectations, the analyst tells investors. Merck guided to “solid” top line growth in 2026 from new launches, but also highlighted an acceleration in operating expense, notes the analyst, who models 2026 EPS of $9.44. Published first on TheFly –",
      "url": "https://finnhub.io/api/news?id=b7ef2271fd9634952dcb5cbdd5f43c7440f141bf1b84b4f6ae6ce041668536e3"
    }
  },
  {
    "ts": null,
    "headline": "Is Eli Lilly a Millionaire Maker?",
    "summary": "Eli Lilly has a leading position in a hot new drug category, but there's one notable problem to consider.",
    "url": "https://finnhub.io/api/news?id=cb321b4d84a7a5e9fce510c60e82a0e19a76dd7c050be7b0b2aafdeb947db7f7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762260300,
      "headline": "Is Eli Lilly a Millionaire Maker?",
      "id": 137312007,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Eli Lilly has a leading position in a hot new drug category, but there's one notable problem to consider.",
      "url": "https://finnhub.io/api/news?id=cb321b4d84a7a5e9fce510c60e82a0e19a76dd7c050be7b0b2aafdeb947db7f7"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer's $4.9 Billion Gamble: Inside Its Legal War to Reclaim the Obesity Market",
    "summary": "After raising its 2025 profit forecast again, Pfizer turns its sights on Novo Nordisk in a billion-dollar obesity drug showdown.",
    "url": "https://finnhub.io/api/news?id=50de7afafe745b3939886e3d14e78919eccaa1601ad168ecbbc0fabc77d3fcb7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762259728,
      "headline": "Pfizer's $4.9 Billion Gamble: Inside Its Legal War to Reclaim the Obesity Market",
      "id": 137312222,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "After raising its 2025 profit forecast again, Pfizer turns its sights on Novo Nordisk in a billion-dollar obesity drug showdown.",
      "url": "https://finnhub.io/api/news?id=50de7afafe745b3939886e3d14e78919eccaa1601ad168ecbbc0fabc77d3fcb7"
    }
  },
  {
    "ts": null,
    "headline": "Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT)",
    "summary": "RAHWAY, N.J., November 04, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the company has entered into an agreement to receive funds managed by Blackstone Life Sciences (\"Blackstone\") for the development of sacituzumab tirumotecan (sac-TMT), an investigational antibody-drug conjugate (ADC) targeting trophoblast cell-surface antigen 2 (TROP2), a protein found on the surface of various cancer cells. Merck is currently evaluating sac-TMT in 15 gl",
    "url": "https://finnhub.io/api/news?id=494522302a1b6df25e82a13b071db149437126ee521620032ad75f7438e11420",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762257000,
      "headline": "Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT)",
      "id": 137312223,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., November 04, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the company has entered into an agreement to receive funds managed by Blackstone Life Sciences (\"Blackstone\") for the development of sacituzumab tirumotecan (sac-TMT), an investigational antibody-drug conjugate (ADC) targeting trophoblast cell-surface antigen 2 (TROP2), a protein found on the surface of various cancer cells. Merck is currently evaluating sac-TMT in 15 gl",
      "url": "https://finnhub.io/api/news?id=494522302a1b6df25e82a13b071db149437126ee521620032ad75f7438e11420"
    }
  },
  {
    "ts": null,
    "headline": "Merck Signs Agreement with Dr. Falk Pharma GmbH for Certain Development and Commercialization Rights to MK-8690 (PRA-052) an Investigational Anti-CD30 Ligand Monoclonal Antibody",
    "summary": "RAHWAY, N.J., November 04, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the company, through a subsidiary (Prometheus BioSciences), has reached an agreement with Dr. Falk Pharma GmbH (Falk) to discontinue an existing contract concerning co-development and co-commercialization rights in certain territories for MK-8690 (formerly PRA-052), and for Merck to assume full responsibility for the development program going forward. MK-8690 is an inves",
    "url": "https://finnhub.io/api/news?id=52a7dccb048c2c499920a2150840d5e7c74bb0532df64b9150b27381df9d56e3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762256700,
      "headline": "Merck Signs Agreement with Dr. Falk Pharma GmbH for Certain Development and Commercialization Rights to MK-8690 (PRA-052) an Investigational Anti-CD30 Ligand Monoclonal Antibody",
      "id": 137312224,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., November 04, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the company, through a subsidiary (Prometheus BioSciences), has reached an agreement with Dr. Falk Pharma GmbH (Falk) to discontinue an existing contract concerning co-development and co-commercialization rights in certain territories for MK-8690 (formerly PRA-052), and for Merck to assume full responsibility for the development program going forward. MK-8690 is an inves",
      "url": "https://finnhub.io/api/news?id=52a7dccb048c2c499920a2150840d5e7c74bb0532df64b9150b27381df9d56e3"
    }
  },
  {
    "ts": null,
    "headline": "Veterinary Monoclonal Antibodies Market Research Global Forecast Report 2025: A $3.06 Billion Market by 2030, Driven by Upcoming Technologies, R&D Activities, and Product Launches",
    "summary": "The global veterinary monoclonal antibodies market is set to surge, reaching USD 3.06 billion by 2030, up from USD 1.70 billion in 2025, with a CAGR of 12.4%. This growth is driven by increasing pet ownership and heightened awareness of chronic diseases in pets. Despite challenges like rising pet care costs and strict regulations, expanding therapeutic uses offer new opportunities. Notably, the canine segment dominates due to the high incidence of skin conditions in dogs. By 2030, the subcutaneo",
    "url": "https://finnhub.io/api/news?id=83bf332603120f1dd090cacc75269928d258713930c64ee8240f641434aa7369",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762255560,
      "headline": "Veterinary Monoclonal Antibodies Market Research Global Forecast Report 2025: A $3.06 Billion Market by 2030, Driven by Upcoming Technologies, R&D Activities, and Product Launches",
      "id": 137312225,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The global veterinary monoclonal antibodies market is set to surge, reaching USD 3.06 billion by 2030, up from USD 1.70 billion in 2025, with a CAGR of 12.4%. This growth is driven by increasing pet ownership and heightened awareness of chronic diseases in pets. Despite challenges like rising pet care costs and strict regulations, expanding therapeutic uses offer new opportunities. Notably, the canine segment dominates due to the high incidence of skin conditions in dogs. By 2030, the subcutaneo",
      "url": "https://finnhub.io/api/news?id=83bf332603120f1dd090cacc75269928d258713930c64ee8240f641434aa7369"
    }
  },
  {
    "ts": null,
    "headline": "Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?",
    "summary": "With yields of up to 7%, this trio of high-yield stocks are all industry-leading companies.",
    "url": "https://finnhub.io/api/news?id=8a32df81f345eb237ed9cd4aa0eca6ff9a713eee58a24d5bda487288f9b67cd9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762248600,
      "headline": "Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?",
      "id": 137312153,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "With yields of up to 7%, this trio of high-yield stocks are all industry-leading companies.",
      "url": "https://finnhub.io/api/news?id=8a32df81f345eb237ed9cd4aa0eca6ff9a713eee58a24d5bda487288f9b67cd9"
    }
  },
  {
    "ts": null,
    "headline": "Does Merck’s 17% Stock Drop in 2025 Signal a Prime Opportunity?",
    "summary": "Wondering if Merck stock is truly a bargain or just priced for perfection? You are not alone. Let's dig into what the numbers and recent developments say about its value. Despite a storied track record, Merck shares have pulled back lately, dropping 6.3% this past week, 7.5% over the last month, and now sit 16.8% lower for the year so far. Recent headlines have highlighted shifts in the pharmaceutical landscape, including regulatory news and developments with competitors in the oncology...",
    "url": "https://finnhub.io/api/news?id=045eb64e003556e84b59aca505aa5b1e2566d90581a40ad7d3f2f66fe6cead5c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762247524,
      "headline": "Does Merck’s 17% Stock Drop in 2025 Signal a Prime Opportunity?",
      "id": 137312227,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Wondering if Merck stock is truly a bargain or just priced for perfection? You are not alone. Let's dig into what the numbers and recent developments say about its value. Despite a storied track record, Merck shares have pulled back lately, dropping 6.3% this past week, 7.5% over the last month, and now sit 16.8% lower for the year so far. Recent headlines have highlighted shifts in the pharmaceutical landscape, including regulatory news and developments with competitors in the oncology...",
      "url": "https://finnhub.io/api/news?id=045eb64e003556e84b59aca505aa5b1e2566d90581a40ad7d3f2f66fe6cead5c"
    }
  },
  {
    "ts": null,
    "headline": "Merck Taking Full Control of MK-8690 Development Program",
    "summary": "Merck Taking Full Control of MK-8690 Development Program",
    "url": "https://finnhub.io/api/news?id=2e3f41445488def5551582884506ce7361126e454f2731cced0e75eacffe28e7",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762242480,
      "headline": "Merck Taking Full Control of MK-8690 Development Program",
      "id": 137317812,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck Taking Full Control of MK-8690 Development Program",
      "url": "https://finnhub.io/api/news?id=2e3f41445488def5551582884506ce7361126e454f2731cced0e75eacffe28e7"
    }
  },
  {
    "ts": null,
    "headline": "Merck Gets $700M from Blackstone Life Sciences for Development of Cancer Drug",
    "summary": "Merck Gets $700M from Blackstone Life Sciences for Development of Cancer Drug",
    "url": "https://finnhub.io/api/news?id=2c0b9067df096cc3f00ad98877d95011fa310a37b3dd0749bb7d313a9b1da97d",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762240800,
      "headline": "Merck Gets $700M from Blackstone Life Sciences for Development of Cancer Drug",
      "id": 137317813,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck Gets $700M from Blackstone Life Sciences for Development of Cancer Drug",
      "url": "https://finnhub.io/api/news?id=2c0b9067df096cc3f00ad98877d95011fa310a37b3dd0749bb7d313a9b1da97d"
    }
  },
  {
    "ts": null,
    "headline": "Morgan Stanley Maintains Merck (MRK) Equal-Weight Recommendation",
    "summary": "Morgan Stanley Maintains Merck (MRK) Equal-Weight Recommendation",
    "url": "https://finnhub.io/api/news?id=eca9ef2dcc09a80a7d2192e1827a1f3f34bee873952ad6d2f8bdcaf669937f62",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762214883,
      "headline": "Morgan Stanley Maintains Merck (MRK) Equal-Weight Recommendation",
      "id": 137308378,
      "image": "",
      "related": "MRK",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=eca9ef2dcc09a80a7d2192e1827a1f3f34bee873952ad6d2f8bdcaf669937f62"
    }
  }
]